How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about lecanemab

Marketing authorisation indication

2.1

Lecanemab (Leqembi, Eisai) is indicated 'for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein Eε 4 (ApoE ε4) heterozygotes or non-carriers'.

Price

2.3

The list price of lecanemab is £275 for 200 mg solution for infusion and £545 for 500 mg solution or infusion (excluding VAT; company submission).

2.4

The company has a commercial arrangement, which would have applied if the lecanemab had been recommended.

Comments panel open